Navigation Links
CV Therapeutics Announces $185 Million Transaction with TPG-Axon Capital for Half of Royalty for Lexiscan(TM) (regadenoson) Injection
Date:4/15/2008

PALO ALTO, Calif., April 15 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX) announced today that TPG-Axon Capital has agreed to pay CV Therapeutics up to $185 million in exchange for rights to 50 percent of CV Therapeutics' royalty on North American sales of Lexiscan(TM) (regadenoson) injection. CV Therapeutics received $175 million on closing of the transaction and could receive a potential future milestone payment of $10 million.

The U.S. Food and Drug Administration (FDA) approved Lexiscan(TM) (regadenoson) injection, an A2A adenosine receptor agonist, for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging (MPI) in patients unable to undergo adequate exercise stress, on April 10, 2008.

CV Therapeutics retains rights to the other 50 percent of royalty revenue from North American sales of the product, and also may receive a royalty on another Astellas product under the terms of the company's collaboration agreement with Astellas Pharma US, Inc.

"With the funds from this non-dilutive financing and multiple product-related revenue streams, we believe CV Therapeutics now has the funds to become cash flow positive and meet the debt obligation which is putable in 2010, both without requiring capital market financing or partnership dollars," said Louis G. Lange, M.D., Ph.D., chairman and chief executive officer of CV Therapeutics. "We are aggressively pursuing a partner to support Ranexa commercialization and this additional financial independence provides important leverage for managing both the balance sheet and our discussions with potential partners."

CV Therapeutics owns the rights for regadenoson outside of North America and currently expects to submit a marketing a
'/>"/>

SOURCE CV Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... , May 20, 2013   Flexion Therapeutics , ... W. Driscoll to its management team as ... years of financial management experience with biotechnology and medical ... Driscoll was chief financial officer for Novavax (NASDAQ: ... secured more than $250 million through a combination of ...
(Date:5/20/2013)... 20, 2013 Recognizing exciting and ... members to its 2013 Class of Young Professors. ... will provide this outstanding international group with more ... basic science to meet global challenges.     , The ... promising young and untenured research faculty working in ...
(Date:5/20/2013)... Culver City, CA (PRWEB) May 20, 2013 ... Trustees has announced the appointment of Lisa Baird as ... WMIS on July 8, 2013. The WMIS ... multi-modal imaging applications to understand and effectively treat diseases ... Molecular Imaging Society (WMIS) was established in 2011 by ...
(Date:5/17/2013)... 2013 Dr. Sparano is Professor of ... at the Albert Einstein College of Medicine and Associate ... Medical Center. He is also Associate Director for ... the Einstein Breast Cancer Working Group, a multidisciplinary group ... research. He also serves as Vice Chair of the ...
Breaking Biology Technology:Flexion Therapeutics Names Frederick Driscoll Chief Financial Officer 2DuPont Celebrates Scientific Innovation by Recognizing Young Professors 2DuPont Celebrates Scientific Innovation by Recognizing Young Professors 3WMIS Appoints Lisa Baird as Next Executive Director 2Joseph A. Sparano, MD, Named Vice Chair of ECOG-ACRIN Cancer Research Group 2Joseph A. Sparano, MD, Named Vice Chair of ECOG-ACRIN Cancer Research Group 3
... Huifeng,Bio-Pharmaceutical Technology, Inc (OTC Bulletin Board: HFGB), ... and pharmaceutical raw materials,for use in pharmaceutical, ... its business following their quarterly report released ... quarter, sales of our products increased substantially,",stated ...
... Isabella,s Health Bakery launched,Activate raisin bran probiotic ... (IDDBA) show in New Orleans.,The new Activate ... health,and are fortified with the high-survivability probiotic, ... http://www.newscom.com/cgi-bin/prnh/20041213/CLM031LOGO ), Isabella,s Healthy Bakery ...
... 3 Catalyst,Pharmaceutical Partners, Inc. (Nasdaq: ... develops and commercializes prescription drugs,for the treatment ... announced the filing of a shelf registration ... After the shelf registration,statement has been declared ...
Cached Biology Technology:Huifeng Bio-Pharmaceutical (HFGB) Provides Update on Current Business and COS Certification 2Isabella's Healthy Bakery Unveils Activate - A New Probiotic Muffin Fortified with GanedenBC30 Probiotic 2Isabella's Healthy Bakery Unveils Activate - A New Probiotic Muffin Fortified with GanedenBC30 Probiotic 3Catalyst Pharmaceutical Partners, Inc. Files Form S-3 Shelf Registration Statement 2Catalyst Pharmaceutical Partners, Inc. Files Form S-3 Shelf Registration Statement 3
(Date:5/17/2013)... MD (May 18, 2013) The AGA Research Foundation ... into the relationship between the gut microbiota, one of ... and disease. , The AGA Research Awards Panel ... from Massachusetts General Hospital and Harvard Medical School, Boston, ... recipient. Dr. Chan will receive $25,000 of funding, commencing ...
(Date:5/17/2013)... China---- Why Tibetan antelope can live at elevations ... collaborative research published in Nature Communications , ... provide evidence that some genetic factors may be ... environments. The data in this work will also ... the biology of other ruminant species. , The ...
(Date:5/16/2013)... (May 17, 2013) Illustrating a commitment to ... American Gastroenterological Association (AGA) Research Foundation has announced ... Research Fellowship Award recipients. Supported by the National ... (NIDDK), this new award helps underrepresented minority students ... and nutrition research. , "By establishing this new ...
Breaking Biology News(10 mins):New gut microbiome research to explore red meat -- colorectal cancer pathway 2The genome sequence of Tibetan antelope sheds new light on high-altitude adaptation 2Underrepresented minority students receive fellowships in digestive disease and nutrition research 2
... Leipzig / Pasadena. Scientists of the Helmholtz Centre ... California Institute of Technology (Caltech) in Pasadena succeeded ... are known to dramatically reduce the oceanic emission ... oxidize methane anaerobically are an important component of ...
... PHILADELPHIA Studying thousands of patients, Japanese researchers have ... risk of three cancers esophageal, head and neck, ... decrease risk of developing these diseases. In the ... journal of the American Association for Cancer Research, scientists ...
... A chemical reaction in genes that control breast ... help researchers more accurately determine a womans risk for ... treatment, UT Southwestern Medical Center researchers have found. ... Cancer Epidemiology Biomarkers & Prevention , scientists from UT ...
Cached Biology News:Deep sea methane scavengers captured 2Deep sea methane scavengers captured 3Tooth loss strongly linked to risk of esophageal, head and neck, and lung cancer 2Molecular 'clock' could predict risk for developing breast cancer 2Molecular 'clock' could predict risk for developing breast cancer 3
... LC Sciences provides a genome-wide microRNA (miRNA) ... proprietary probe design, which enable highly sensitive ... We have standard arrays for mature miRNA ... version of the Sanger miRBase database (Release ...
... immunological studies, vaccine development, and biosensor ... powerful Paraflo microfluidic on-chip synthesis platform. ... of our comprehensive Epitope Peptide Microarray ... Probe content is completely customer ...
... Custom peptide microarrays designed for quantitative ... samples and built on the flexible ... Thousands of customer specified sequences can ... can provide assistance with custom sequence ...
... Now, for the first time, you can ... and more efficiently without interferences. The Agilent ... remove unwanted, multiple high-abundant proteins from human ... with just one device. With this revolutionary ...
Biology Products: